Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)

Authors not listed

Apellis Pharmaceuticals, Inc. · 2015

Abstract

The objective of this study is to provide initial safety, tolerability and pharmacokinetics information of intravitreal administration of pegcetacoplan in order to support further development into larger Phase II studies for treatment of patients with AMD.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Anonymous. (2015). Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD). <em>Apellis Pharmaceuticals, Inc.</em>. https://clinicaltrials.gov/study/NCT02461771
Vancouver
Anonymous. Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD). Apellis Pharmaceuticals, Inc.. 2015.
BibTeX
@misc{anon2015Assess, title = {Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)}, author = {Anonymous}, journal = {Apellis Pharmaceuticals, Inc.}, year = {2015}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings